A Study to Evaluate the Effects of Basmisanil in Participants With Cognitive Impairment Associated With Schizophrenia (CIAS) Treated With Antipsychotics

Inclusion Criteria: * Diagnosis of schizophrenia of any type utilizing the Mini International Neuropsychiatric Interview and diagnostic and statistical manual of mental disorders, fifth edition (DSM-5) direct clinical assessments, family informants and past medical records * Evidence of stability of symptoms for 3 months at screening, that is, without hospitalizations for schizophrenia or increase in level of psychiatric care due to worsening of symptoms of schizophrenia * Participants with schizophrenia clinical symptom severity defined by the following: hallucinatory behavior item score less than or equal to (\</=) 5 and a delusion item score \</= 5 of the PANSS * Participants on a stable regimen of antipsychotic therapy for at least 3 months at screening and receiving no more than two antipsychotics Exclusion Criteria: * Participants with current DSM-5 diagnosis other than schizophrenia including bipolar disorder, schizoaffective disorder and major depressive disorder * Clinically significant neurological illness or significant head trauma that affects cognitive function, in the judgment of the principal investigator * Full scale intelligence quotient \</=65 on the Wechsler Abbreviated Scale of Intelligence at screening * Positive result at screening for hepatitis B, hepatitis C, or human immunodeficiency virus-1 and 2 * Moderate to severe substance use disorder (other than nicotine or caffeine), as defined by the DSM-5, within the last 12 months * Suicide attempt withi…